PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Analyze analyst forecasts for the company and compare them with competitors.
42.82M
Worse than MDGL's estimated revenue of 2.85B.
-8.56M
Worse than MDGL's estimated ebitda of 0.
-0.59
Worse than MDGL's estimated eps of 52.48.
-17.89M
Worse than MDGL's estimated net income of 980.70M.
-8.56M
Worse than MDGL's estimated ebit of 0.
1.59B
Worse than MDGL's estimated sg&a expense of 0.
Analyze DCF forecasts for the company and compare them with competitors.
No Data
No DCF data available for this metric in the selected year.
-100.00%
Worse than MDGL's revenue growth rate of 0.00%.
-37.43M
Better than MDGL's ebitda of -450.13M.
100.00%
Better than MDGL's ebitda margin of -249.88%.
-38.24M
Better than MDGL's ebit of -451.22M.
100.00%
Better than MDGL's ebit margin of -250.49%.
811.00K
Better than MDGL's depreciation of 1.10M.
72.90M
Worse than MDGL's total cash of 926.25M.
100.00%
Worse than MDGL's cash as percentage of revenue of 514.20%.
No Data
No DCF data available for this metric in the selected year.
100.00%
Worse than MDGL's receivables as percentage of revenue of 29.88%.
No Data
No DCF data available for this metric in the selected year.
100.00%
Worse than MDGL's inventories as percentage of revenue of 18.91%.
No Data
No DCF data available for this metric in the selected year.
100.00%
Worse than MDGL's payables as percentage of revenue of 24.20%.
-11.00K
Worse than MDGL's capital expenditure of -1.46M.
100.00%
Worse than MDGL's capex as percentage of revenue of -0.81%.
4.99%
Better than MDGL's weighted average cost of capital (wacc) of 5.15%.
5.02%
Worse than MDGL's cost of equity of 5.01%.
4.08%
Better than MDGL's cost of debt of 12.27%.
-0.23
Worse than MDGL's beta of -0.92.
30.07M
Worse than MDGL's diluted shares outstanding of 21.27M.
1.57M
Better than MDGL's total debt of 119.57M.
49.31M
Worse than MDGL's total equity of 6.18B.
50.89M
Worse than MDGL's total capital of 6.30B.
3.09%
Worse than MDGL's debt weighting of 1.90%.
96.91%
Worse than MDGL's equity weighting of 98.10%.
-38.24M
Better than MDGL's ebiat of -451.22M.
-45.40M
Better than MDGL's unlevered free cash flow of -523.92M.
2.00%
Equal to MDGL's long-term growth rate of 2.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Better than MDGL's net debt of 19.55M.
71.33M
Worse than MDGL's equity value of 7.30B.
2.37
Worse than MDGL's equity value per share of 343.00.
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Analysts expect the stock price to increase by 521.91%.
Buy
Positive consensus among analysts.